NCT00313209|CompletedPhase 3Results

Effect of Roflumilast on Lung Function in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Salmeterol: The EOS Study (BY217/M2-127)

EOS

Effect of Roflumilast in COPD Patients Treated With Salmeterol. A 24-week, Double-blind Study With 500 μg Roflumilast Once Daily Versus Placebo. The EOS Study

AstraZeneca ClinicalTrials.gov

Compare

2 other identifiers

BY217/M2-1272005-005080-28

Study Type

interventional

Target

933

Locations

10 countries

Sites

134

Timeline

RegisteredApr 2006

StartedApr 2006

CompletionFeb 2008

Brief Summary

The aim of the study is to compare the efficacy of roflumilast on pulmonary function and symptomatic parameters in patients with chronic obstructive pulmonary disease (COPD) during concomitant administration of salmeterol. The study duration will last up to 28 weeks. The study will provide further data on safety and tolerability of roflumilast.

Trial Health

On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Strong global presence with extensive site network

Enrollment

933

participants targeted

Target at P75+ for phase_3

Timeline

Completed

Started Apr 2006

Geographic Reach

10 countries

134 active sites

Status

completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

1.8 years study duration

Study Start

First participant enrolled

April 1, 2006

Completed

10 days until next milestone

First Submitted

Initial submission to the registry

April 11, 2006

Completed

1 day until next milestone

First Posted

Study publicly available on registry

April 12, 2006

Completed

1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2007

Completed

7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2008

Completed

3.3 years until next milestone

Results Posted

Study results publicly available

May 19, 2011

Completed

Last Updated

December 14, 2016

Status Verified

November 1, 2016

Enrollment Period

1.2 years

First QC Date

April 11, 2006

Results QC Date

March 17, 2011

Last Update Submit

November 1, 2016

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Keywords

RoflumilastSalmeterolCOPDChronic obstructive pulmonary disease

Outcome Measures

Primary Outcomes (1)

Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1)
Mean change from baseline during the treatment period in pre-bronchodilator FEV1 \[L\]
Change from baseline over 24 weeks of treatment

Secondary Outcomes (4)

Post-bronchodilator FEV1
Change from baseline over 24 weeks of treatment
COPD Exacerbation Rate (Mild, Moderate or Severe)
24 weeks treatment period
Transition Dyspnea Index (TDI) Focal Score
Change from baseline over 24 weeks of treatment
Shortness of Breath Questionnaire (SOBQ) Total Score
Change from baseline over 24 weeks of treatment

Study Arms (2)

Roflumilast

ACTIVE COMPARATOR

Roflumilast 500 µg underlying medication: salmeterol 50 μg, twice daily, inhaled

Drug: Roflumilast

Placebo

PLACEBO COMPARATOR

Placebo underlying medication: salmeterol 50 μg, twice daily, inhaled

Drug: Placebo

Interventions

RoflumilastDRUG

500 µg, once daily, oral administration in the morning

Roflumilast

PlaceboDRUG

once daily

Placebo

Eligibility Criteria

Age40 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

History of COPD for at least 12 months prior to baseline visit
FEV1/FVC ratio (post-bronchodilator) ≤ 70%
FEV1 (post-bronchodilator) between ≥ 40% and ≤ 70% of predicted

You may not qualify if:

COPD exacerbation indicated by a treatment with systemic glucocorticosteroids and/or antibiotics not stopped at least 4 weeks prior to baseline visit

Contact the study team to confirm eligibility.